SUWON, Republic of Korea, Sept. 24, 2021 (GLOBE NEWSWIRE) — OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a number one developer of RNAi therapeutics, in the present day introduced that the Firm will current new knowledge throughout its pipeline on the 2021 Oligonucleotide Therapeutics Society Virtual Conference, being held just about September 26-29, 2021.
Key knowledge embody preclinical research outcomes for its investigational therapeutic focusing on hepatitis B virus (HBV) and OLX702A, an investigational RNAi therapeutic for the therapy of nonalcoholic steatohepatitis (NASH). OliX previously announced that OLX702A reversed tissue injury within the liver in a mouse mannequin of NASH.
OliX will even current an summary of its pipeline OLX101A for hypertrophic scars, OLX104C for hair loss, OLX301A/D for age-related macular degeneration and subretinal fibrosis. The Firm expects to provoke scientific trials for OLX104C and OLX301A/D in 2022.
Titles for the pre-recorded poster displays are under:
GalNAc-conjugated RNAi Therapeutics by OliX Prescribed drugs (2021-P-236-OTS)
Growth of Cell-penetrating Uneven siRNA Therapeutics Concentrating on Pores and skin Illnesses, Hypertrophic Scar and Androgenetic Alopecia
Nonclinical Growth of Novel Cell-penetrating Uneven Small Interfering RNA Concentrating on Genes for Superior Age-related Macular Degeneration (2021-P242-OTS)
RIG-I-mediated Innate Immune Stimulation by Chemically Synthesized Lengthy Double-stranded RNAs is Construction- and Sequence-dependent (2021-P-224-OTS)
About OliX Prescribed drugs
OliX Prescribed drugs is a scientific stage pharmaceutical firm growing therapeutics towards quite a lot of problems by down-regulating expression of disease-causing genes, based mostly by itself proprietary RNAi expertise. The Firm’s core RNAi platform, uneven siRNA (asiRNA), is a novel gene silencing expertise based mostly on RNA interference (RNAi), which is taken into account essentially the most environment friendly gene silencing expertise. Based mostly on asiRNA expertise, OliX has developed cell penetrating asiRNA (cp-asiRNA), a therapeutic RNAi platform to successfully goal domestically administrable ailments, similar to hypertrophic scar, dry and moist age-related macular degeneration (AMD), subretinal fibrosis, idiopathic pulmonary fibrosis (IPF), and neuropathic ache. OliX has additionally developed one other therapeutic RNAi platform, GalNAc-asiRNA, to focus on quite a lot of liver ailments. For extra data, please go to: https://www.olixpharma.com/eng